A Weight Loss Study in Overweight Men and Women

Overview[ - collapse ][ - ]

Purpose The purpose of this study is to determine if LY377604 + sibutramine work better than LY377604 or sibutramine alone in the treatment of obesity.
ConditionObesity
InterventionDrug: LY377604
Drug: Sibutramine
Drug: Metoprolol
Drug: Placebo sibutramine
Drug: Placebo Metoprolol
Drug: Placebo LY377604
PhasePhase 2
SponsorEli Lilly and Company
Responsible PartyEli Lilly and Company
ClinicalTrials.gov IdentifierNCT00993421
First ReceivedOctober 9, 2009
Last UpdatedJune 2, 2011
Last verifiedJune 2011

Tracking Information[ + expand ][ + ]

First Received DateOctober 9, 2009
Last Updated DateJune 2, 2011
Start DateOctober 2009
Estimated Primary Completion DateJune 2010
Current Primary Outcome MeasuresPercent Change in Body Weight From Baseline to 24 Week Endpoint [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]Body weight percentage change from baseline is presented as Least Squares Mean (LSMean) with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline body weight, age, gender were used as covariates.
Current Secondary Outcome Measures
  • The Mean Change in Body Weight From Baseline to 24 Week Endpoint [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]Body weight change from baseline is presented as Least Squares Mean (LSMean) with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline body weight, age, gender were used as covariates.
  • Percentage of Participants Who Achieve a Minimum of 10% Weight Loss From Baseline at 24 Weeks [Time Frame: 24 weeks] [Designated as safety issue: No]
  • Change in Heart Rate From Baseline to 24 Week Endpoint [Time Frame: Baseline, 24 weeks] [Designated as safety issue: Yes]Heart rate change from baseline is presented as Least Squares Mean (LSMean) with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline heart rate, age, gender were used as covariates.
  • Change in Blood Pressure From Baseline to 24 Week Endpoint [Time Frame: Baseline, 24 weeks] [Designated as safety issue: Yes]Blood pressure change from baseline is presented as Least Squares Mean (LSMean) with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline blood pressure, age, gender were used as covariates.
  • Change in Body Composition Using Dual Energy X-ray Absorptiometry (DXA) From Baseline to 24 Week Endpoint [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]Change in body composition (lean body mass and fat mass) was assessed using dual energy x-ray absorptiometry (DXA) and is presented as LSMEAN values with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline body composition, age, gender were used as covariates.
  • Change in Waist Circumference From Baseline to 24 Week Endpoint [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]Change from baseline to endpoint is presented as LSMEAN with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline waist circumference, age, gender were used as covariates.
  • Percentage Change in Waist Circumference From Baseline to 24 Week Endpoint [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]Percentage change from baseline to endpoint is presented as LSMEAN with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline waist circumference, age, gender were used as covariates.
  • Change in Total Cholesterol From Baseline to 24 Weeks Endpoint [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]
  • Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to 24 Weeks Endpoint [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]
  • Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to 24 Weeks Endpoint [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]
  • Change in Triglycerides From Baseline to 24 Weeks Endpoint [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]
  • Change From Baseline for Obesity Weight Loss Quality of Life Instrument (OWL-QoL) [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]Results presented as Least Squares Mean with treatment, visit, and their interaction as fixed effects, subject as random effect, baseline body mass index used as covariate. OWL-QoL consists of 17 items on scale ranging from 0 (Not at all) to 6 (A very great deal). Before calculating scores, each item is reversed. A single quality of life score is computed by summing each item and transforming this raw score onto standardized scale of 0 (greatest impact) to 100 (lowest impact) using formula: score = [(sum of component items score (minus) lowest possible score/ possible raw score range)*100].
  • Change From Baseline in Vitality Scale of Medical Outcomes Short Form - 36 (SF-36) Scale [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]Vitality change from baseline is presented as Least Squares Mean (LSMean) with treatment, visit, and their interaction as fixed effects, subject as a random effect, baseline body mass index was used as covariate. SF-36 is a self-reported questionnaire that consists of 36 questions covering 8 health domains including vitality. The vitality domain results are presented. The vitality domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning.
  • Change in Glycated Hemoglobin A1c (HbA1c) From Baseline [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]Analysis of change in HbA1c was not conducted due to an inadequate number of samples.
  • Change in Fasting Glucose From Baseline to 24 Weeks Endpoint [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]Analysis of change in fasting glucose was not conducted due to an inadequate number of samples.
  • Change in Fasting Insulin From Baseline to 24 Weeks Endpoint [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]Analysis of change in fasting insulin was not conducted due to an inadequate number of samples.
  • Change in Insulin Resistance From Baseline to 24 Weeks Endpoint [Time Frame: Baseline, 24 weeks] [Designated as safety issue: No]Analysis of change in insulin resistance was not conducted due to an inadequate number of samples.
  • Pharmacokinetics: Area Under the Concentration Time Curve (AUC) [Time Frame: 4 weeks, 12 weeks, and 24 weeks] [Designated as safety issue: No]Analysis of AUC was not conducted due to an inadequate number of samples collected.
  • Pharmacokinetics: Maximum Concentration (Cmax) [Time Frame: 4 weeks, 12 weeks, and 24 weeks] [Designated as safety issue: No]Analysis of Cmax was not conducted due to an inadequate number of samples collected.

Descriptive Information[ + expand ][ + ]

Brief TitleA Weight Loss Study in Overweight Men and Women
Official TitleLY377604 + Sibutramine Hydrochloride Monohydrate: A Phase 2 Weight Loss Efficacy Study in Overweight/Obese Men and Women
Brief Summary
The purpose of this study is to determine if LY377604 + sibutramine work better than
LY377604 or sibutramine alone in the treatment of obesity.
Detailed DescriptionNot Provided
Study TypeInterventional
Study PhasePhase 2
Study DesignAllocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
ConditionObesity
InterventionDrug: LY377604
Given daily, orally for 24 weeks
Drug: Sibutramine
given daily, orally for 24 weeks
Drug: Metoprolol
given daily, orally for 24 weeks (100 mg for 1 week followed by 200 mg for 23 weeks. Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by a 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).
Drug: Placebo sibutramine
given daily, orally for 24 weeks
Drug: Placebo Metoprolol
given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
Drug: Placebo LY377604
given daily, orally for 24 weeks
Study Arm (s)
  • Placebo Comparator: placebo
  • Experimental: LY377604 (75 mg)
  • Active Comparator: sibutramine (30 mg)/metoprolol (200 mg)
  • Experimental: LY377604 (40 mg)/sibutramine (30 mg)
  • Experimental: LY377604 (75 mg)/sibutramine (30 mg)
  • Experimental: LY377604 (15 mg)/sibutramine (30 mg)
  • Experimental: LY377604 (75 mg)/sibutramine (15 mg)

Recruitment Information[ + expand ][ + ]

Recruitment StatusTerminated
Estimated Enrollment343
Estimated Completion DateJune 2010
Estimated Primary Completion DateJune 2010
Eligibility Criteria
Inclusion Criteria:

- Are between the body mass index (BMI) of 27 and 45 kg/m^2, inclusive, at the time of
screening.

Exclusion Criteria:

- Have a Diastolic Blood Pressure (DBP) greater than 90 mm Hg or less than 55 mm Hg,
and/or Systolic Blood Pressure (SBP) >140 mm Hg or <90 mmHg, confirmed by at least 1
repeat measurement. Subjects with hypertension treated with antihypertensive
medication are not excluded if blood pressure is within the prescribed limits and
they are not treated with excluded medications. Changes in antihypertensive
medication are not permitted within 30 days prior to randomization

- Previous history of poorly controlled hypertension, (that is, >160/100 or
hypertension which requires more than 2 drugs for control).

- Have a pulse rate >90 bpm or <50 bpm.

- Evidence or history of prior significant cardiovascular disease, coronary artery
disease, cardiovascular surgery, significant valvular disease, heart failure,
arrhythmias, sick sinus syndrome or stroke.

- Current treatment with β-blockers, calcium channel blockers, digitalis glycosides
(for example, digoxin, etc), or clonidine.

- Recent treatment (within 2 weeks prior to randomization) with catecholamine-depleting
drugs (such as reserpine or tetrabenazine, monoamine oxidase inhibitors (MAOIs).

- Current treatment with serotonergic drugs, such as selective serotonin reuptake
inhibitors (SSRI), any drug that is a serotonin, norepinephrine, or dopamine reuptake
inhibitor, "triptan" or ergot therapies for migraine or nausea, or
serotonin-releasing agents.

- Treatment with significant inhibitors of Cytochrome P2D6 (CYP2D6), such as bupropion,
fluoxetine, paroxetine, quinidine, duloxetine, amiodarone, cimetidine,
chlorpheniramine, clomipramine, doxepin, haloperidol, methadone, mibefradil, and
ritonavir.

- Participants with bronchospastic diseases or who are treated with bronchodilators or
other prescription or nonprescription beta adrenergic agonists.

- Peripheral vascular disease

- History of thyrotoxicosis

- History of seizures (except for childhood febrile convulsion) or at increased risk of
seizures (for example, history of significant head trauma or intracranial surgery).

- Have had a significant change in weight, defined as a gain or loss of at least 4 kg
(9 lb) in the 90 days prior to randomization

- Have had bariatric surgery (for example, gastric banding or gastric bypass)

- Have had liposuction within 90 days prior to randomization

- Have a disease that affects adipose mass or distribution of energy balance (for
example, Cushing's syndrome, uncontrolled hyper- or hypothyroidism).

- Have taken in the 30 days prior to randomization, a medication, herbal product, or
nutritional supplement that affects adipose mass or distribution or energy balance,
such as glucocorticoids, antiretrovirals, atypical antipsychotics, lithium, valproic
acid, lamotrigine, or other anticonvulsants, mirtazapine, bupropion, phentermine,
sibutramine, orlistat, rimonabant, amphetamine, or ephedra-containing supplements.
Note: Medications that have small and transient effects on weight or medications
that may affect weight independent of adipose mass (for example, estrogens or
diuretics), may be continued, but may not be started, stopped, or changed during the
course of the study.

- Have been diagnosed with an eating disorder, such as anorexia, bulimia, binge eating
disorder, or nocturnal eating disorder.

- Have diabetes mellitus treated with medication, or type 2 diabetes mellitus managed
with diet and exercise with hemoglobin A1c (HbA1C) >7.0%.

- Symptomatic cholelithiasis in the 90 days prior to randomization.

- Any lifetime history of suicide attempt.

- History of major depressive disorder in the last 2 years or any lifetime history of
severe psychiatric disorders (for example, schizophrenia or bipolar disorder).
GenderBoth
Ages21 Years
Accepts Healthy VolunteersNo
ContactsNot Provided
Location CountriesUnited States

Administrative Information[ + expand ][ + ]

NCT Number NCT00993421
Other Study ID Numbers11892
Has Data Monitoring CommitteeYes
Information Provided ByEli Lilly and Company
Study SponsorEli Lilly and Company
CollaboratorsNot Provided
Investigators Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM-5 PM Eastern time (UTC/GMT-5 hours, EST) Eli Lilly and Company
Verification DateJune 2011

Locations[ + expand ][ + ]

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Mesa, Arizona, United States, 85201
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Concord, California, United States, 94520
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
La Jolla, California, United States, 92037
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Waterbury, Connecticut, United States, 06708
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
South Miami, Florida, United States, 33143
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Idaho Falls, Idaho, United States, 83404
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Avon, Indiana, United States, 46123
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Bloomington, Indiana, United States, 47403
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Carmel, Indiana, United States, 46032
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Indianapolis, Indiana, United States, 46260
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Des Moines, Iowa, United States, 50314
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Topeka, Kansas, United States, 66606
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Baton Rouge, Louisiana, United States, 70808
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Haverhill, Massachusetts, United States, 01830
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Sterling Heights, Michigan, United States, 48314
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Minneapolis, Minnesota, United States, 55416
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Las Vegas, Nevada, United States, 89130
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Wilmington, North Carolina, United States, 28401
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Portland, Oregon, United States, 97210
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Dallas, Texas, United States, 75230
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Richmond, Virginia, United States, 23233